New pharmacological approaches for obesity management

Obesity, which results from an imbalance between calorie intake and expenditure, now affects over 500 million individuals worldwide. Lifestyle and behavioural interventions aimed at reducing calorie intake and/or increasing energy expenditure have limited long-term effectiveness due to complex and persistent hormonal, metabolic and neurochemical adaptations that defend against weight loss and promote weight regain. Surgical treatments for obesity, although highly effective, are unavailable or unsuitable for many individuals with excess adiposity. Accordingly, few effective treatment options are available to most obese individuals. In the past, the use of antiobesity drugs, seemingly the logical choice to fill this therapeutic gap, has been limited because of a lack of efficacy, poor long-term adherence rates and serious adverse effects, such as valvulopathy. Recently, the FDA has approved two new medications: lorcaserin and phentermine–topiramate controlled release, and is currently reviewing the resubmission of naltrexone sustained release–bupropion sustained release. This Review presents the available data on the efficacy and safety of these three medications, and discusses future perspectives and challenges related to pharmacological weight management.